Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Carbamazepine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A known ✓ | P35499 | 1/20 | 0.96 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.96 |
| ▸ | SCN9A known ✓ | Q15858 | 1/20 | 0.96 |
| ▸ | LMNA | P02545 | 1/20 | 0.96 |
| ▸ | TSHR | P16473 | 1/20 | 0.96 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.96 |
| ▸ | P2RX4 | Q99571 | 16/20 | 0.72 |
| ▸ | BCHE | P06276 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | P2RX1 | P51575 | 5/20 | 0.55 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.55 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.55 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbamazepine SCHEMBL29390487 | 1.00 | LMNA (0.96) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL5382102 | 1.00 | LMNA (0.96) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL6477112 | 0.98 | LMNA (1.00) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL21639 | 0.98 | LMNA (1.00) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL29433237 | 0.98 | LMNA (1.00) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL31685158 | 0.98 | LMNA (1.00) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL29360181 | 0.98 | LMNA (1.00) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL29023618 | 0.96 | LMNA (0.96) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL28169915 | 0.96 | LMNA (0.96) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL27589204 | 0.96 | LMNA (0.96) | LMNATSHRMAPK1SCN4ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210129406-A1 | DRUG SOLVATES IN THERMAL PROCESSES TO MAKE SOLID DISPERSIONS AT LOWER PROCESSING TEMPERATURES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-05-06 | — | — | US | claimed |
| EP-0289977-B1 | SUSTAINED-RELEASE ORAL ADMINISTRATION FORMS | CIBA-GEIGY AG (CH) | 1993-09-15 | — | — | EP | claimed |
| US-5122543-A | Syrup of carbamazepine in protective polymeric colloid | CIBA-GEIGY CORPORATION (US) | 1992-06-16 | — | — | US | claimed |
| US-12303594-B2 | Antimicrobial and anti-inflammatory compositions | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2025-05-20 | — | — | US | disclosed |
| US-20230346697-A1 | ANTIMICROBIAL AND ANTI-INFLAMMATORY COMPOSITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-02 | — | — | US | disclosed |
| US-11723864-B2 | Antimicrobial and anti-inflammatory compositions | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2023-08-15 | — | — | US | disclosed |
| CN-114768292-A | Control method for self-assembled film induced carbamazepine crystal form and online monitoring method for crystallization process | 天津科技大学 | 2022-07-22 | — | — | CN | disclosed |
| US-20210129406-A1 | DRUG SOLVATES IN THERMAL PROCESSES TO MAKE SOLID DISPERSIONS AT LOWER PROCESSING TEMPERATURES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-05-06 | — | — | US | disclosed |
| EP-3459535-B1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2020-08-12 | — | — | EP | disclosed |
| US-20200155491-A1 | THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2020-05-21 | — | — | US | disclosed |
| US-10463640-B2 | Therapeutic approaches for treating CMT and related disorders | PHARNEXT (FR) | 2019-11-05 | — | — | US | disclosed |
| US-5888545-A | Carbamazepine medicament with retarded active substance release | ARZNEIMITTELWERK DRESDEN GMBH (DE) | 1999-03-30 | — | — | US | disclosed |
| EP-0768882-B1 | CARBAMAZEPINE MEDICAMENT WITH RETARDED ACTIVE SUBSTANCE RELEASE | DRESDEN ARZNEIMITTEL (DE) | 1998-08-19 | — | — | EP | disclosed |
| CN-1153475-A | Carbamazepine medicament with retarded active substance release | DRESDEN ARZNEIMITTEL (DE) | 1997-07-02 | — | — | CN | disclosed |
| CN-1153475-A | Carbamazepine medicament with retarded active substance release | DRESDEN ARZNEIMITTEL (DE) | 1997-07-02 | — | — | CN | disclosed |
| EP-0768882-A1 | CARBAMAZEPINE MEDICAMENT WITH RETARDED ACTIVE SUBSTANCE RELEASE | ARZNEIMITTELWERK DRESDEN GmbH (DE) | 1997-04-23 | — | — | EP | disclosed |
| WO-1996001112-A1 | CARBAMAZEPINE MEDICAMENT WITH RETARDED ACTIVE SUBSTANCE RELEASE | ARZNEIMITTELWERK DRESDEN GMBH (DE) | 1996-01-18 | — | — | WO | disclosed |
| US-RE34990-E | Anticonvulsants, treatment of epilepsy, carbamazepine | CIBA-GEIGY CORPORATION (US) | 1995-07-04 | — | — | US | disclosed |
| US-5122543-A | Syrup of carbamazepine in protective polymeric colloid | CIBA-GEIGY CORPORATION (US) | 1992-06-16 | — | — | US | disclosed |
| US-4857336-A | Oral therapeutic system having systemic action | CIBA-GEIGY CORPORATION (US) | 1989-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210129406-A1 | DRUG SOLVATES IN THERMAL PROCESSES TO MAKE SOLID DISPERSIONS AT LOWER PROCESSING TEMPERATURES | HPSE, LIPA, ABCG2 | SCN4A 3183/4885SCN5A 3240/4885SCN9A 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.